235 related articles for article (PubMed ID: 17515522)
41. Quality of life and psychological distress in patients with cutaneous lymphoma.
Sampogna F; Frontani M; Baliva G; Lombardo GA; Alvetreti G; Di Pietro C; Tabolli S; Russo G; Abeni D
Br J Dermatol; 2009 Apr; 160(4):815-22. PubMed ID: 19120325
[TBL] [Abstract][Full Text] [Related]
42. Current management strategies for cutaneous T-cell lymphoma.
Knobler E
Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous T-cell lymphoma and cutaneous graft-versus-host disease. Two indications for photopheresis in dermatology.
Girardi M; Heald PW
Dermatol Clin; 2000 Jul; 18(3):417-23, viii. PubMed ID: 10943537
[TBL] [Abstract][Full Text] [Related]
44. Cutaneous T-cell lymphoma: a case study, treatment, and nursing implications.
Harris JS; Macey WH
Dermatol Nurs; 1994 Feb; 6(1):41-9. PubMed ID: 7946828
[TBL] [Abstract][Full Text] [Related]
45. Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma.
Tran J; Morris L; Vu A; Reddy S; Duvic M
Dermatol Online J; 2020 Sep; 26(9):. PubMed ID: 33054950
[TBL] [Abstract][Full Text] [Related]
46. Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection.
Wolfe JT; Lessin SR; Singh AH; Rook AH
Artif Organs; 1994 Dec; 18(12):888-97. PubMed ID: 7887825
[TBL] [Abstract][Full Text] [Related]
47. [Photopheresis for cutaneous T-cell lymphomas].
Laroche L
Ann Dermatol Venereol; 2005 Sep; 132 Spec No 2():5S37-8. PubMed ID: 16385898
[No Abstract] [Full Text] [Related]
48. Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.
Eshagh K; Romero LS; So JK; Zhao XF
Cutis; 2017 Feb; 99(2):E30-E34. PubMed ID: 28319634
[TBL] [Abstract][Full Text] [Related]
49. Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
Liu HL; Kim YH
Arch Dermatol; 2002 Mar; 138(3):398-9. PubMed ID: 11902993
[No Abstract] [Full Text] [Related]
50. Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.
Kreuter A; Altmeyer P; Gambichler T
Acta Derm Venereol; 2006; 86(3):274-5. PubMed ID: 16710601
[No Abstract] [Full Text] [Related]
51. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
[No Abstract] [Full Text] [Related]
52. Extracorporeal photopheresis.
Treen N
J Vis Commun Med; 2010 Mar; 33(1):31-3. PubMed ID: 20297912
[No Abstract] [Full Text] [Related]
53. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
[TBL] [Abstract][Full Text] [Related]
54. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
55. The therapeutic potential of extracorporeal photopheresis.
Girardi M
Clin Adv Hematol Oncol; 2006 May; 4(5):349-50. PubMed ID: 16728944
[No Abstract] [Full Text] [Related]
56. Cutaneous gamma/delta T-cell lymphoma treated with retinoid and narrowband ultraviolet B.
Nakashima H; Sugaya M; Minatani Y; Ohmatsu H; Asano N; Fujimoto M; Kikuchi K; Ihn H; Tamaki K
Clin Exp Dermatol; 2009 Oct; 34(7):e345-6. PubMed ID: 19456763
[No Abstract] [Full Text] [Related]
57. [Extracorporeal photopheresis].
Prinz B; Plewig G
Hautarzt; 1994 Nov; 45(11):746-50. PubMed ID: 7822197
[TBL] [Abstract][Full Text] [Related]
58. Update on treatment of cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
[TBL] [Abstract][Full Text] [Related]
59. The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
Br J Dermatol; 2023 Oct; 189(5):e97. PubMed ID: 37879744
[No Abstract] [Full Text] [Related]
60. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy.
Huber MA; Kunzi-Rapp K; Staib G; Scharffetter-Kochanek K
J Am Acad Dermatol; 2004 Mar; 50(3):475-6. PubMed ID: 14988696
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
